Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study

Martin Salgueiro, Michael Stribos, Li Fang Zhang, Mark R Stevens, Mohamed E. Awad, Mohammed Elsayed Elsalanty

Research output: Contribution to journalArticle

Abstract

Objectives: The low incidence yet severe presentation of medication-related osteonecrosis of the jaw (MRONJ) makes it necessary to develop reliable predictive and preventive strategies. This study explored the value of pre-operative carboxy-terminal collagen crosslinks (CTX) serum level in the prediction of osteonecrosis-related complications in patients on bisphosphonate therapy. Patients and methods: We examined patient records over 4 years (a total of 137 patients). Biometric data were extracted, in addition to type of treatment, CTX levels, drug holiday, procedure, complications, and co-morbidities. Non-parametric Wilcoxon two-sample tests were used to test the effect of initial CTX level in IV or PO and whether it was predictive of complications. Two independent proportion tests were used for testing the two different complication incident rates before or after the drug holiday. Results: A total of 93 patients were included in the study, of whom 88.17% were female. A total of 11 patients were receiving IV bisphosphonates at the time of initial presentation, 82 oral bisphosphonates. Out of 64 patients who underwent invasive dental procedure (IDP) before a drug holiday, eight were on IV bisphosphonates. Three patients in this group experienced osteonecrosis-related complications (37.5%). Out of the remaining 56 patients on oral bisphosphonates, four (7.14%) developed complications, significantly lower than the IV bisphosphonate group (p = 0.0364). On the other hand, of the 34 patients placed on a drug holiday prior to IDP, only one subject developed complications related to osteonecrosis. Five subjects who had operations both before and after drug holiday did not experience any complications. No statistical difference was detected in complication rates based on initial CTX level (above versus below 150 pg/ml), gender, comorbidities, or total duration of bisphosphonate treatment (p = 0.2675). The sensitivity and specificity of CTX cutoff of 150 pg/ml in predicting osteonecrosis were 37.5% and 57.7, respectively. Conclusions: Serum levels of CTX by itself are not reliable as a predictive or preventive measure for such complications. Our data also suggested that a drug holiday of 5 months was not helpful in preventing osteonecrosis-related complications in patients on intravenous bisphosphonates. Further studies are urgently needed to develop adequate predictive and preventive strategies of MRONJ.

Original languageEnglish (US)
Pages (from-to)21-29
Number of pages9
JournalEPMA Journal
Volume10
Issue number1
DOIs
StatePublished - Mar 1 2019

Fingerprint

Osteonecrosis
Diphosphonates
Jaw
Retrospective Studies
Holidays
Serum
Pharmaceutical Preparations
Tooth
Clinical Studies
Biometrics
Collagen
Comorbidity
Therapeutics
Testing
Morbidity

Keywords

  • Bisphosphonates
  • Drug holiday
  • Osteonecrosis
  • Osteoporosis treatment
  • Prediction of complications

ASJC Scopus subject areas

  • Drug Discovery
  • Health Policy
  • Biochemistry, medical

Cite this

Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ) : a retrospective clinical study. / Salgueiro, Martin; Stribos, Michael; Zhang, Li Fang; Stevens, Mark R; Awad, Mohamed E.; Elsalanty, Mohammed Elsayed.

In: EPMA Journal, Vol. 10, No. 1, 01.03.2019, p. 21-29.

Research output: Contribution to journalArticle

@article{84bc1bb6ed614acab5c49dc998bbc343,
title = "Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study",
abstract = "Objectives: The low incidence yet severe presentation of medication-related osteonecrosis of the jaw (MRONJ) makes it necessary to develop reliable predictive and preventive strategies. This study explored the value of pre-operative carboxy-terminal collagen crosslinks (CTX) serum level in the prediction of osteonecrosis-related complications in patients on bisphosphonate therapy. Patients and methods: We examined patient records over 4 years (a total of 137 patients). Biometric data were extracted, in addition to type of treatment, CTX levels, drug holiday, procedure, complications, and co-morbidities. Non-parametric Wilcoxon two-sample tests were used to test the effect of initial CTX level in IV or PO and whether it was predictive of complications. Two independent proportion tests were used for testing the two different complication incident rates before or after the drug holiday. Results: A total of 93 patients were included in the study, of whom 88.17{\%} were female. A total of 11 patients were receiving IV bisphosphonates at the time of initial presentation, 82 oral bisphosphonates. Out of 64 patients who underwent invasive dental procedure (IDP) before a drug holiday, eight were on IV bisphosphonates. Three patients in this group experienced osteonecrosis-related complications (37.5{\%}). Out of the remaining 56 patients on oral bisphosphonates, four (7.14{\%}) developed complications, significantly lower than the IV bisphosphonate group (p = 0.0364). On the other hand, of the 34 patients placed on a drug holiday prior to IDP, only one subject developed complications related to osteonecrosis. Five subjects who had operations both before and after drug holiday did not experience any complications. No statistical difference was detected in complication rates based on initial CTX level (above versus below 150 pg/ml), gender, comorbidities, or total duration of bisphosphonate treatment (p = 0.2675). The sensitivity and specificity of CTX cutoff of 150 pg/ml in predicting osteonecrosis were 37.5{\%} and 57.7, respectively. Conclusions: Serum levels of CTX by itself are not reliable as a predictive or preventive measure for such complications. Our data also suggested that a drug holiday of 5 months was not helpful in preventing osteonecrosis-related complications in patients on intravenous bisphosphonates. Further studies are urgently needed to develop adequate predictive and preventive strategies of MRONJ.",
keywords = "Bisphosphonates, Drug holiday, Osteonecrosis, Osteoporosis treatment, Prediction of complications",
author = "Martin Salgueiro and Michael Stribos and Zhang, {Li Fang} and Stevens, {Mark R} and Awad, {Mohamed E.} and Elsalanty, {Mohammed Elsayed}",
year = "2019",
month = "3",
day = "1",
doi = "10.1007/s13167-019-0160-3",
language = "English (US)",
volume = "10",
pages = "21--29",
journal = "The EPMA Journal",
issn = "1878-5077",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ)

T2 - a retrospective clinical study

AU - Salgueiro, Martin

AU - Stribos, Michael

AU - Zhang, Li Fang

AU - Stevens, Mark R

AU - Awad, Mohamed E.

AU - Elsalanty, Mohammed Elsayed

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Objectives: The low incidence yet severe presentation of medication-related osteonecrosis of the jaw (MRONJ) makes it necessary to develop reliable predictive and preventive strategies. This study explored the value of pre-operative carboxy-terminal collagen crosslinks (CTX) serum level in the prediction of osteonecrosis-related complications in patients on bisphosphonate therapy. Patients and methods: We examined patient records over 4 years (a total of 137 patients). Biometric data were extracted, in addition to type of treatment, CTX levels, drug holiday, procedure, complications, and co-morbidities. Non-parametric Wilcoxon two-sample tests were used to test the effect of initial CTX level in IV or PO and whether it was predictive of complications. Two independent proportion tests were used for testing the two different complication incident rates before or after the drug holiday. Results: A total of 93 patients were included in the study, of whom 88.17% were female. A total of 11 patients were receiving IV bisphosphonates at the time of initial presentation, 82 oral bisphosphonates. Out of 64 patients who underwent invasive dental procedure (IDP) before a drug holiday, eight were on IV bisphosphonates. Three patients in this group experienced osteonecrosis-related complications (37.5%). Out of the remaining 56 patients on oral bisphosphonates, four (7.14%) developed complications, significantly lower than the IV bisphosphonate group (p = 0.0364). On the other hand, of the 34 patients placed on a drug holiday prior to IDP, only one subject developed complications related to osteonecrosis. Five subjects who had operations both before and after drug holiday did not experience any complications. No statistical difference was detected in complication rates based on initial CTX level (above versus below 150 pg/ml), gender, comorbidities, or total duration of bisphosphonate treatment (p = 0.2675). The sensitivity and specificity of CTX cutoff of 150 pg/ml in predicting osteonecrosis were 37.5% and 57.7, respectively. Conclusions: Serum levels of CTX by itself are not reliable as a predictive or preventive measure for such complications. Our data also suggested that a drug holiday of 5 months was not helpful in preventing osteonecrosis-related complications in patients on intravenous bisphosphonates. Further studies are urgently needed to develop adequate predictive and preventive strategies of MRONJ.

AB - Objectives: The low incidence yet severe presentation of medication-related osteonecrosis of the jaw (MRONJ) makes it necessary to develop reliable predictive and preventive strategies. This study explored the value of pre-operative carboxy-terminal collagen crosslinks (CTX) serum level in the prediction of osteonecrosis-related complications in patients on bisphosphonate therapy. Patients and methods: We examined patient records over 4 years (a total of 137 patients). Biometric data were extracted, in addition to type of treatment, CTX levels, drug holiday, procedure, complications, and co-morbidities. Non-parametric Wilcoxon two-sample tests were used to test the effect of initial CTX level in IV or PO and whether it was predictive of complications. Two independent proportion tests were used for testing the two different complication incident rates before or after the drug holiday. Results: A total of 93 patients were included in the study, of whom 88.17% were female. A total of 11 patients were receiving IV bisphosphonates at the time of initial presentation, 82 oral bisphosphonates. Out of 64 patients who underwent invasive dental procedure (IDP) before a drug holiday, eight were on IV bisphosphonates. Three patients in this group experienced osteonecrosis-related complications (37.5%). Out of the remaining 56 patients on oral bisphosphonates, four (7.14%) developed complications, significantly lower than the IV bisphosphonate group (p = 0.0364). On the other hand, of the 34 patients placed on a drug holiday prior to IDP, only one subject developed complications related to osteonecrosis. Five subjects who had operations both before and after drug holiday did not experience any complications. No statistical difference was detected in complication rates based on initial CTX level (above versus below 150 pg/ml), gender, comorbidities, or total duration of bisphosphonate treatment (p = 0.2675). The sensitivity and specificity of CTX cutoff of 150 pg/ml in predicting osteonecrosis were 37.5% and 57.7, respectively. Conclusions: Serum levels of CTX by itself are not reliable as a predictive or preventive measure for such complications. Our data also suggested that a drug holiday of 5 months was not helpful in preventing osteonecrosis-related complications in patients on intravenous bisphosphonates. Further studies are urgently needed to develop adequate predictive and preventive strategies of MRONJ.

KW - Bisphosphonates

KW - Drug holiday

KW - Osteonecrosis

KW - Osteoporosis treatment

KW - Prediction of complications

UR - http://www.scopus.com/inward/record.url?scp=85063066903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063066903&partnerID=8YFLogxK

U2 - 10.1007/s13167-019-0160-3

DO - 10.1007/s13167-019-0160-3

M3 - Article

AN - SCOPUS:85063066903

VL - 10

SP - 21

EP - 29

JO - The EPMA Journal

JF - The EPMA Journal

SN - 1878-5077

IS - 1

ER -